Author

J. P. Loftus

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Approach:statistical model· 2 Research Focus:cell type annotation· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1 Assay:proteomics· 1

Frequent Co-Authors

S. K. Tasian· 3 shared A. Kumar· 1 shared A. Thomas-Tikhonenko· 1 shared C. D. Falkenstein· 1 shared C. Hurtz· 1 shared C. Schmidt· 1 shared D. H. Allen· 1 shared E. Chong· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

S. K. Tasian

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Alternative splicing of its 5'-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapies

Z. Ang, L. Paruzzo, K. E. Hayer, C. Schmidt, M. Torres Diz, F. Xu, U. Zankharia, Y. Zhang, S. Soldan, S. Zheng, C. D. Falkenstein, J. P. Loftus, S. Y. Yang, M. Asnani, P. King Sainos, , A. Thomas-Tikhonenko

This study identifies alternative splicing of CD20 mRNA that generates translation-deficient isoforms, contributing to resistance to CD20-directed immunotherapies.

bioRxiv · Feb 19, 2023Immunology

Pharmacologic Inhibition of DYRK1A Results in MYC Hyperactivation and ERK Hyperphosphorylation rendering KMT2A-R ALL Cells Sensitive to BCL2 Inhibition

C. Hurtz, V. S. S. A. Ayyadevara, G. Wertheim, J. Chukinas, J. P. Loftus, S. J. Lee, A. Kumar, R. S. Bhansali, S. Swaminathan, H. Geng, T. Milne, X. Hua, K. M. Bernt, T. Besson, J. Shi, , S. K. Tasian

This study shows that inhibiting DYRK1A in KMT2A-R ALL cells leads to MYC upregulation and ERK hyperphosphorylation, making them sensitive to BCL2 inhibition.

bioRxiv · Oct 2, 2022 · PreprintCancer Biology

Network Analysis Reveals Synergistic Genetic Dependencies for Rational Combination Therapy in Philadelphia Chromosome-like Acute Lymphoblastic Leukemia

Y.-Y. Ding, H. Kim, K. Madden, J. P. Loftus, G. M. Chen, D. H. Allen, R. Zhang, J. Xu, Y. Hu, S. K. Tasian, K. Tan

The paper identifies synergistic genetic targets in Ph-like B-ALL using network analysis to guide combination therapy, showing improved efficacy in preclinical models.

bioRxiv · Jan 6, 2021Cancer Biology